Activity Evaluation and Mode of Action of ICA Against Toxoplasma gondii In Vitro

Area of Science:

• Parasitology
• Infectious Diseases
• Drug Discovery

Background:

• Toxoplasmosis is a major zoonotic parasitic disease with no available vaccine.
• Current treatments for toxoplasmosis rely on chemotherapy, but limitations exist for existing drugs.
• There is a critical need for novel, safe, and effective anti-Toxoplasma gondii medications.

Purpose of the Study:

• To evaluate the toxicity and anti-Toxoplasma gondii effects of ICA (N-(pyridin-2-yl)-4-(pyridine-2-yl)thiazol-2-amine).
• To investigate the impact of ICA on T. gondii tachyzoites' ultrastructure and mitochondrial function.
• To assess ICA's potential as a lead compound for new anti-toxoplasmosis therapies.

Main Methods:

• Toxicity assessment of ICA on host cells.
• Evaluation of ICA's inhibitory and anti-proliferative effects on T. gondii tachyzoites.
• Transmission electron microscopy (TEM) to observe ultrastructural changes.
• Measurement of mitochondrial membrane potential, superoxide, and ATP levels.

Main Results:

• ICA demonstrated a safe and effective inhibitory effect on T. gondii with a high selectivity index (SI) of 258.25.
• ICA exhibited a more potent anti-proliferative effect compared to pyrimethamine (PYR).
• Ultrastructural analysis revealed ICA induces mitochondrial swelling and membrane rupture, leading to mitochondrial dysfunction in T. gondii.

Conclusions:

• ICA shows significant potential as a novel therapeutic agent against T. gondii.
• The compound's mechanism involves inducing mitochondrial dysfunction in the parasite.
• ICA could serve as a valuable lead compound for developing new treatments for toxoplasmosis.